Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily.

Abstract:

:Oral therapy for chronic hepatitis B remains suboptimal. Mathematical modelling of viral decay kinetics to rapidly assess potential antiviral regimens has proved valuable for human immunodeficiency virus and cytomegalovirus. We defined the kinetics of viral replication in 10 chronic hepatitis B patients randomized to lamivudine 100 mg vs 600 mg for 48 weeks. Viral decay kinetics conformed to a biphasic pattern in nine of 10 subjects. Persons receiving 600 mg daily of lamivudine exhibited a 1.6-fold faster decay rate in the infected cell compartment (0.028/day vs 0.017/day, P = 0.06) and a greater overall change in serum viral load when compared with those receiving 100 mg (4.06 vs 1.52 log(10) copies/mL, P = 0.08). More potent therapy appeared to result in more rapid decrease in the infected cell population. Studies using mathematical modelling of viral decay may be a useful method to evaluate single or combination therapy for HBV infection in vivo.

journal_name

J Viral Hepat

authors

Wang CC,Holte S,Huang ML,Sacks SL,Engelberg R,Ferrenberg J,Shuhart M,Corey L

doi

10.1111/j.1365-2893.2004.00523.x

subject

Has Abstract

pub_date

2004-09-01 00:00:00

pages

443-7

issue

5

eissn

1352-0504

issn

1365-2893

pii

JVH523

journal_volume

11

pub_type

临床试验,杂志文章,随机对照试验
  • Change in injecting behaviour among people treated for hepatitis C virus: The role of intimate partnerships.

    abstract::Injecting behaviour in people who inject drugs is the main risk factor for hepatitis C virus (HCV) infection. Psychosocial factors such as having a partner who injects drugs and living with other drug users have been associated with increases in injecting risk behaviour. This study aimed to investigate changes in inje...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/jvh.13009

    authors: Malaguti A,Sani F,Stephens BP,Ahmad F,Dugard P,Dillon JF,ERADICATE-C Study Group.

    更新日期:2019-01-01 00:00:00

  • Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus.

    abstract::Hepatitis C virus (HCV) is a human hepatotropic virus, but many hepatoma cell lines are not permissive to this virus. In a previous study, we observed that SNU-182, SNU-398 and SNU-449 hepatoma cell lines were nonpermissive to HCV. To understand the nonpermissivity, we evaluated the ability of each cell line to suppor...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12767

    authors: Fournier C,Hoffmann TW,Morel V,Descamps V,Dubuisson J,Brochot E,Francois C,Duverlie G,Castelain S,Helle F

    更新日期:2018-01-01 00:00:00

  • Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium.

    abstract::In Italy, HDV infection endemicity has greatly decreased overtime. Migratory flow may change this scenario as migrants often come from high HDV endemicity areas. Here, we studied characteristics of HDV infection in Italy, particularly addressed to the birth area of subjects. Chronic HBsAg carriers consecutively referr...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13310

    authors: Stroffolini T,Ciancio A,Furlan C,Vinci M,Fontana R,Russello M,Colloredo G,Morisco F,Coppola N,Babudieri S,Ferrigno L,Sagnelli C,Sagnelli E

    更新日期:2020-09-01 00:00:00

  • Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.

    abstract::Chronic hepatitis B (CHB) is characterized by an impaired immune response to hepatitis B virus. Among the nucleos(t)ides used in CHB treatment, telbivudine is associated with the highest rates of hepatitis B e antigen (HBeAg) seroconversion rates, which are similar to those observed with pegylated interferon (PegIFN)....

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12059

    authors: Wang GQ,Ding YP,Dong YH

    更新日期:2013-04-01 00:00:00

  • Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade.

    abstract::With the approval of 2 direct-acting antivirals (DAAs) in 2011 and anticipation of interferon (IFN)-free regimens, more hepatitis C virus (HCV) chronically infected patients are now seeking treatment. To describe the characteristics of newly referred HCV patients in 2011-2012 (Era-2) and compare them to those seen in ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12343

    authors: Talaat N,Yapali S,Fontana RJ,Conjeevaram HS,Lok AS

    更新日期:2015-05-01 00:00:00

  • Hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cells of treatment naïve chronically infected patients.

    abstract::Peripheral blood mononuclear cells (PBMCs) from 45 treatment naïve, HIV-negative, chronically hepatitis C virus (HCV)-infected patients were analyzed for the presence of HCV RNA. Viral RNA was detected in 73% of the studied patients. Single-strand conformation polymorphism assays and sequence analysis of the HCV 5'unt...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01112.x

    authors: Vera-Otarola J,Barría MI,León U,Marsac D,Carvallo P,Soza A,López-Lastra M

    更新日期:2009-09-01 00:00:00

  • Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.

    abstract::High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic h...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2002.00370.x

    authors: Di Marco V,Ferraro D,Almasio P,Vaccaro A,Parisi P,Cappello M,Cino N,Di Stefano R,Craxì A

    更新日期:2002-09-01 00:00:00

  • Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

    abstract::Liver damage may result from multiple factors in HIV-infected patients. The availability of reliable noninvasive tools to measure liver fibrosis has permitted the screening of large patient populations. Cross-sectional study of all consecutive HIV outpatients who underwent examination by transient elastometry (FibroSc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01261.x

    authors: Blanco F,Barreiro P,Ryan P,Vispo E,Martín-Carbonero L,Tuma P,Labarga P,Medrano J,González-Lahoz J,Soriano V

    更新日期:2011-01-01 00:00:00

  • Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases.

    abstract::Chronic hepatitis C virus (HCV) infection leads to mixed cryoglobulinaemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Aberrant somatic hypermutation and deregulation of the oncogene BCL-6 is associated with lymphomagenesis. Recently, HCV was shown to induce BCL-6 mutations in vitro. The BCL-6 gene (area B) was clon...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00833.x

    authors: Hofmann WP,Fernandez B,Herrmann E,Welsch C,Mihm U,Kronenberger B,Feldmann G,Spengler U,Zeuzem S,Sarrazin C

    更新日期:2007-07-01 00:00:00

  • Simian hepatitis A virus derived from a captive rhesus monkey in India is similar to the strain isolated from wild African green monkeys in Kenya.

    abstract:SUMMARY:A simian hepatitis A virus (HAV) was identified retrospectively in a faecal sample from a rhesus monkey in India, inoculated in 1995 with a faecal suspension from a suspected patient of non-A to E hepatitis. The monkey was in captivity for 2 years in one of the experimental primate facilities in western India b...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.01060.x

    authors: Arankalle VA,Ramakrishnan J

    更新日期:2009-03-01 00:00:00

  • Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.

    abstract::Although the incidence of new hepatitis C virus (HCV) infection has fallen, HCV-related complications are on the rise. Our aim was to assess and describe the 2005-2009 national inpatient mortality and resource utilization trends for patients with HCV. Data from the National Inpatient Sample (NIS) and the National Hosp...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12262

    authors: Younossi ZM,Otgonsuren M,Henry L,Arsalla Z,Stepnaova M,Mishra A,Venkatesan C,Hunt S

    更新日期:2015-02-01 00:00:00

  • Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.

    abstract::Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNα). The ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2011.01560.x

    authors: Mederacke I,Yurdaydin C,Großhennig A,Erhardt A,Cakaloglu Y,Yalcin K,Gurel S,Zeuzem S,Zachou K,Chatzikyrkou C,Bozkaya H,Dalekos GN,Manns MP,Wedemeyer H,Hep-Net\/International Delta Hepatitis Study Group.

    更新日期:2012-06-01 00:00:00

  • Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma.

    abstract::Advanced age and high hepatitis B virus (HBV) DNA level are risk factors associated with the development of HBV-related hepatocellular carcinoma (HCC). However, little is known about the role of viral load in the carcinogenesis of HCC in young people. A total of 183 HBV-related HCC patients and 202 HBV carriers were t...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00780.x

    authors: Tsai FC,Liu CJ,Chen CL,Chen PJ,Lai MY,Kao JH,Chen DS

    更新日期:2007-03-01 00:00:00

  • Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection.

    abstract::In rare cases, individuals with a history of long-term injecting drug use remain seronegative and aviraemic, despite prolonged and likely repeated exposure to Hepatitis C virus (HCV) through high-risk behaviour. We describe anti-HCV Envelope (E) antibody responses in a prospective cohort of carefully defined highly ex...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13339

    authors: Mina M,Underwood A,Eltahla A,Wu BR,Walker MR,Bull RA,Lloyd AR

    更新日期:2020-10-01 00:00:00

  • Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers.

    abstract::In 1996, a combined vaccine against both hepatitis A and B was licensed and commercialized and has been recommended for healthcare personnel in Belgium. This study compares the immunogenicity against hepatitis B virus (HBV) and safety of two vaccination schedules (0-1-12 months and 0-1-6 months) with this vaccine. Thi...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2010.01365.x

    authors: De Schryver A,Verstrepen K,Vandersmissen L,Vandermeeren N,Vernaillen I,Vranckx R,Van Damme P,van Sprundel M

    更新日期:2011-04-01 00:00:00

  • Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial.

    abstract::The efficacy and tolerability of 12-month treatment with titrated doses of recombinant interferon-alpha 2a (IFN-alpha 2a) in chronic hepatitis C were studied in 67 consecutively recruited patients randomly assigned either to a starting dose of IFN-alpha 2a 6 MU, subsequently adjusted to the serum alanine aminotransfer...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.1995.tb00009.x

    authors: Rumi MG,del Ninno E,Parravicini ML,Romeo R,Soffredini R,Donato MF,Zahm F,Colombo M

    更新日期:1995-01-01 00:00:00

  • Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.

    abstract::Infection with the hepatitis C virus (HCV) remains chronic in 75% of infected individuals, in whom it can cause liver inflammation and progressive fibrosis leading to cirrhosis in 20% of patients. A sustained viral response (SVR) to HCV therapy, i.e. undetectable plasma HCV RNA 6 months after the end of treatment, lea...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2004.00506.x

    authors: Bräu N

    更新日期:2004-05-01 00:00:00

  • Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.

    abstract::In this pilot study, we evaluated the efficacy of interferon-alpha (IFN) plus Thymosin-alpha 1 (TA1) to that of IFN alone in naive patients with chronic hepatitis C. Twenty-two patients were randomized to receive interferon-alpha 2b (3 million units three times a week) plus thymosin-alpha l (900 microg/m2 body surface...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2893.2003.00470.x

    authors: Andreone P,Gramenzi A,Cursaro C,Felline F,Loggi E,D'Errico A,Spinosa M,Lorenzini S,Biselli M,Bernardi M

    更新日期:2004-01-01 00:00:00

  • Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia.

    abstract::An estimated incidence of hepatocellular carcinoma (HCC) in Mongolia is currently one of the highest in the world. According to previous reports, the sero-prevalence of hepatitis B (HBV) and hepatitis C (HCV) viruses in general population of the country is very high (HBV, 10% and HCV, 15%, respectively). Moreover, the...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00864.x

    authors: Kurbanov F,Tanaka Y,Elkady A,Oyunsuren T,Mizokami M

    更新日期:2007-09-01 00:00:00

  • The burden of hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.

    abstract::Cameroon is thought to have one of the highest prevalences of hepatitis C virus (HCV) infection in the world (4.9% among adults). A marked cohort effect exists in several communities where ≈50% of the elderly are infected. Better assessment of HCV distribution is needed for planning treatment programmes. We tested for...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12894

    authors: Njouom R,Siffert I,Texier G,Lachenal G,Tejiokem MC,Pépin J,Fontanet A

    更新日期:2018-08-01 00:00:00

  • Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis.

    abstract::A simple, pangenotypic and effective treatment regimen for patients with a broad range of chronic hepatitis C virus (HCV) infections remains an unmet medical need. We conducted a phase 2, randomized, open study involving untreated patients with chronic HCV genotypes 1, 2, 3, or 6 infections. Patients without cirrhosis...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13208

    authors: Rao H,Song G,Li G,Yang Y,Wu X,Guan Y,Mao Q,Jiang X,Wang C,Zhang Y,Jia J,Guo X,Li C,Ning J,Qin H,Pan H,Wei L

    更新日期:2020-01-01 00:00:00

  • Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis.

    abstract::Endoglin, a transforming growth factor (TGF)-beta1 co-receptor, has been associated with renal and cutaneous fibrosis, as overexpression of this protein has been observed in biopsies from patients with glomerulosclerosis and scleroderma, respectively. Our aim was to evaluate whether endoglin may be associated with hep...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00733.x

    authors: Clemente M,Núñez O,Lorente R,Rincón D,Matilla A,Salcedo M,Catalina MV,Ripoll C,Iacono OL,Bañares R,Clemente G,García-Monzón C

    更新日期:2006-09-01 00:00:00

  • Adefovir serum levels do not differ between responders and nonresponders.

    abstract::Primary or secondary failure of adefovir dipivoxil (ADV) therapy of chronic hepatitis B is not infrequent. The reasons for suboptimal responses are not well defined. In HIV and hepatitis C virus infection, failure of antiviral drug therapy has been linked with low blood drug levels. We have studied 20 well-defined pat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01404.x

    authors: Deterding K,Naesens L,Buti M,Janssen H,Kirschner J,Guerrero A,Reijnders J,Neyts J,Zoulim F,Wedemeyer H

    更新日期:2011-07-01 00:00:00

  • Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.

    abstract::CH-C negatively affects work productivity (WP), creating a large economic burden. The aim of this study was to model the impact of sustained virologic response (SVR) on WP in CHC genotype 1 (GT1) patients in five European countries (EU5). Work Productivity and Activity Index-Specific Health Problem questionnaire was a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12483

    authors: Younossi Z,Brown A,Buti M,Fagiuoli S,Mauss S,Rosenberg W,Serfaty L,Srivastava A,Smith N,Stepanova M,Beckerman R

    更新日期:2016-03-01 00:00:00

  • GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.

    abstract::GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-associated variants (RAVs). In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/jvh.12527

    authors: Rodriguez-Torres M,Glass S,Hill J,Freilich B,Hassman D,Di Bisceglie AM,Taylor JG,Kirby BJ,Dvory-Sobol H,Yang JC,An D,Stamm LM,Brainard DM,Kim S,Krefetz D,Smith W,Marbury T,Lawitz E

    更新日期:2016-08-01 00:00:00

  • Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infection.

    abstract::Previously, we have determined that human annexin V (hAV), a Ca2+-dependent phospholipid-binding protein, and not rat AV, binds specifically to small hepatitis B surface antigen (SHBsAg), and that transfection of a rat hepatoma cell line with a construct containing the hAV gene led to hAV expression and conferred susc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2000.00207.x

    authors: De Meyer S,Gong ZJ,Hertogs K,Depla E,van Pelt JF,Roskams T,Maertens G,Yap SH

    更新日期:2000-03-01 00:00:00

  • Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.

    abstract::Hepatitis C virus (HCV) is commonly transmitted by intravenous drug use (IDU) but drug users are under represented in many treatment cohorts, this is because of the assumption of lowered treatment success. We assessed HCV treatment outcomes in active intravenous drug users and patients on opiate substitution therapy. ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01446.x

    authors: Jafferbhoy H,Miller MH,Dunbar JK,Tait J,McLeod S,Dillon JF

    更新日期:2012-02-01 00:00:00

  • Interferon alpha in the treatment of chronic hepatitis C in children: a meta-analysis [correction of metanalysis].

    abstract::Children with chronic hepatitis C may be ideal candidates for treatment with interferon alpha (IFNalpha) as they have liver disease at an early stage. However, adverse drug reactions need to be considered. The aim of this study was to conduct a systematic review of literature on interferon therapy of chronic hepatitis...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,meta分析,评审

    doi:10.1046/j.1365-2893.2003.00420.x

    authors: Di Ciommo V,Russo P,Ravà L,Caprino L

    更新日期:2003-05-01 00:00:00

  • Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells.

    abstract::Dendritic cells (DCs) in chronic hepatitis C patients display impaired function, although the details remain unclear. To investigate the hepatitis C virus (HCV) protein that has the most impact on DC function, we compared five recombinant proteins and seven HCV protein genes in modulating DC phenotype and function. Im...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01213.x

    authors: Takaki A,Tatsukawa M,Iwasaki Y,Koike K,Noguchi Y,Shiraha H,Sakaguchi K,Nakayama E,Yamamoto K

    更新日期:2010-08-01 00:00:00

  • The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia.

    abstract::Treating chronic hepatitis C with pegylated interferon alpha may induce or exacerbate psychiatric illness including depression, mania and aggressive behaviour. There is limited data regarding treatment in the context of chronic schizophrenia. We sought to establish the safety and efficacy of treating patients with sch...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12234

    authors: Mustafa MZ,Schofield J,Mills PR,Priest M,Fox R,Datta S,Morris J,Forrest EH,Gillespie R,Stanley AJ,Barclay ST

    更新日期:2014-07-01 00:00:00